Suchergebnisse
Adma Biologics (ADMA) Laps the Stock Market: Here's Why
In the latest close session, Adma Biologics (ADMA) was up +1.22% at $9.95. The stock's performance was ahead of the S&P 500's daily gain of 0.62%. Elsewhere, the Dow gained 0.58%, while the
Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?
ADMA Biologics ADMA markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
Asceniv, its lead product, is a plasma-derived IVIG
Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Adma Biologics (ADMA) closed at $9.01, marking a -1.53% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 2.91% for the day
Is ADMA Poised for Margin Growth and Supply Expansion in 2026?
ADMA Biologics ADMA markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
Gross margin improved to 57.4% in 2025 from 51.5% in
Gensight Biologics SA
WKN: A2ANGZ / Name: Gensight / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
Innovent Biologics, Inc.
WKN: A2N7N8 / Name: Innovent Biologics / Aktie / Small Cap /
Heat Biologics Inc.
WKN: A2QJR8 / Symbol: HBTX / Name: Heat Biologics / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
Wuxi Biologics (cayman) Inc.
WKN: A2PQ3Q / Name: Wuxi Biologics (cayman) Inc. / Aktie / ? /
Synthetic Biologics Inc.
WKN: A3DMG6 / Symbol: SYN / Name: Synthetic Biologics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /